Experimental approaches and drugs in development for the treatment of dementia

Expert Opinion on Investigational Drugs

Volumn 10, Issue 4, 2001, Pages 607-617

  Emre, M ^a   Qizilbash, N ^a  

^a GLAXOSMITHKLINE   (Spain)

Author keywords

Alzheimer's disease; Dementia; Drug development; Experimental therapy; Treatment

Indexed keywords

1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL; 2 (2 OXO 1 PYRROLIDINYL) N (5,6,7,8 TETRAHYDRO 2,3 DIMETHYLFURO[2,3 B]QUINOLIN 4 YL)ACETAMIDE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACETYLCHOLINE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; AMPAKINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; ESTROGEN; EXCITATORY AMINO ACID RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROPEPTIDE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; SEROTONIN; SEROTONIN 4 AGONIST; SL 650102; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; XR 543;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR DISORDER; CHEMOPROPHYLAXIS; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; DEMENTIA; HUMAN; HUMAN EXPERIMENT; MODULATION; NONHUMAN; NORMAL HUMAN; PATHOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; SYMPTOM; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; DEMENTIA; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEUROTRANSMITTER AGENTS; NOOTROPIC AGENTS;

EID: 0035075379     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.4.607     Document Type: Review

References (101)

1. Potential treatment of Alzheimer's disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like and cytoprotective properties
2. Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist
3. Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers
4. Progress in the understanding and treatment of Alzheimer's disease
5. α-2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat
6. Guanfacine but not clonidine, improves planning and working memory performance in humans
7. Guanfacine and clonidine, α 2-agonists, improve paired associates learning but not delayed matching to sample, in humans
8. A pilot study of clonidine plus physostigmine in Alzheimer's disease
9. Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease
10. Ondansetron in the treatment of cognitive decline in Alzheimer's dementia
11. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset
12. SL65.0102, a novel and selective partial agonist at 5-HT4 receptors improves learning and memory in rodents
13. Enhancement by an ampakine of memory encoding in humans
14. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans
15. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat
16. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP
17. Protection by memantine against A-β (1-40) - Induced neurodegenaration in the CA1 subfield
18. Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia
19. D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain
20. Evaluation of cycloserine in the treatment of Alzheimer's disease
21. D-Cycloserine enhances implicit memory in Alzheimer patients
22. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
23. Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: A rational approach for the development of cognition enhancers
24. Effects of S-8510, a novel benzodiazepine receptor partial inverse agonist, on basal forebrain lesioning-induced dysfunction in rats
25. Therapeutic efficacy of vincamine in dementia
26. Efficacy and safety of BMY 21,502 in Alzheimer's disease
27. Electrophysiological evaluation of the demented state and the nootropic effect of TA-0910 by 'automated fluctuation analysis' of the high frequency EEG. Relation between neuropsychological test results and Lorentzian parameters
28. Effects of a sustained release formulation of thyrotropin-releasing hormone on behavioral abnormalities in senescence-accelerated mice
29. NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems
30. Thyrotropin response to thyrotropin-releasing hormone in patients with dementia of the Alzheimer type
31. Effect of neuropeptides on cognitive function
32. Posatirelin for the treatment of late-onset Alzheimer's disease: A double-blind multicentre study vs. citicoline and ascorbic acid
33. The search for disease-modifying treatment for Alzheimer's disease
34. Testosterone treatment in Alzheimer's disease and healthy older men
35. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
36. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease
37. Divalproex: A possible treatment alternative for demented, elderly aggressive patients
38. Melatonin replacement therapy for rest-activity rhythm disorders in patients with senile dementia of Alzheimer's type
39. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease
40. Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease
41. Cognitive enhancement therapy for Alzheimer's disease. The way forward
42. Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells
43. Nicotine receptor stimulation protects neurons against glutamate- and amyloid-B-induced cytotoxicity
44. Regulated formation of Golgi secretory vesicles containing Alzheimer β-amyloid precursor protein
45. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red
46. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicine: Its possible function as a hydroxyl radical scavenger
47. Hemin and related porphyrins inhibit β-amyloid aggregation
48. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide
49. β-sheet breaker peptides prevent the formation of fibrillar amyloid-β deposits
50. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
51. Dual anti-amyloidogenic and anti-oxidant properties of melatonin: A new therapy for Alzheimer's disease
52. Neuronal kinase stimulation leads to abberant tau phosphorylation and neurotoxicity
53. Regulation of tau phosphorylation in Alzheimer's disease
54. Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention
55. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1
56. Modulation of the phosphorylation state of tau in situ: The roles of calcium and cyclic AMP
57. Modulation of tau hyperphosphorylation in apoE-deficient mice by muscarinic activation and closed head injury
58. Isoform-specific interactions of apolipoproteinE with the microtubule-associated protein MAP2c: Implications for Alzheimer's disease
59. Binding of human apolipoprotein E to synthetic amyloid β-peptide: Isoform specific effects and implication for late-onset Alzheimer's disease
60. Apolipoprotein E allele-specific anti-oxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides
61. Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer's disease brain are related to apolipoprotein E genotype
62. Apolipoprotein E, β-amyloid and the molecular pathology of Alzheimer's disease: Therapeutic implications
63. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
64. Immunomodulators: A new role for statins?
65. Statins (HMG-CoA reductase inhibitors) as a novel type of immunosuppressor
66. Folsom Cardiovascular risk factors and cognitive decline in middle-aged adults
67. Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyl-transferase, NGF receptor and size of medial septum cholinergic neurons
68. Rediscovering an old friend, IGF-1: Potential use in the treatment of neurodegenerative diseases
69. Ameloriation of cholinergic neurone atrophy and spatial memory impairment in aged rats by nerve growth factor
70. Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with lesions of the nucleus basalis magnocellularis
71. Human nerve growth factor improves spatial memory in aged but not young rats
72. Nerve growth factor affects 11c-nicotinic binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient
73. Effect of AIT-082, a purine analog, on working memory in normal and aged mice
74. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrown from PC12 cells
75. Stimulation of nerve growth factor biosynthesis in developing rat brain by reserpine: Steroids as potential mediators
76. Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia
77. Orally-active NGF synthesis stimulators: Potential therapeutic agents in Alzheimer's disease
78. Reversal of age dependant cognitive impairments and cholinergic neurone atrophy by NGF-secreting neuronal progenitors grafted to the basal forebrain
79. Delivery of insulin-like growth factor-1 (IGF-1) to the brain via the olfactory pathway: A possible therapeutic strategy for Alzheimer's disease
80. Immunocytochemical localization of nuclear estrogen receptors and progestin receptors within the rat dorsal raphe nucleus
81. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides
82. Effectiveness of the MAO-B inhibitor, Lazabemide (Ro 19-6327), on the progression of Alzheimer's disease
83. Experience with the RIM-B Lazabemide in Alzheimer's disease
84. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats
85. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
86. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study
87. Schon I: 4-(1-Naphthylamino) -piperidines as inhibitors of lipid peroxidation
88. Sabeluzole stabilizes the neuronal cytoskeleton
89. Priming of cultered neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death
90. Treatment of Alzheimer's disease with sabeluzole: Functional and structural correlates
91. Oral cytokine administration-therapeutic approaches to Alzheimer's disease
92. Novel neuroprotective strategy for Alzheimer's disease: Inhalation of fatty neuropeptides
93. Posatirelin in the treatment of vascular dementia: A double-blind multicentre study versus placebo
94. Multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia
95. Comparative study of nicardipine versus placebo in the prevention of cognitive deterioration in patients with transient ischemic attack
96. Trifusal in the prevention of vascular dementia
97. Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results
98. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
99. Fronto-temporal dementia: Treatment response to serotonin-selective re-uptake inhibitors
100. MRC BHFHeart Protection Study of cholesterol-lowering therapy and of anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
101. New drugs in development